Cart
sales@molnova.com
AZD 5069
CAS No. 878385-84-3
AZD 5069( AZD5069 | AZD-5069 )
Catalog No. M16376 CAS No. 878385-84-3
AZD 5069 (AZD5069)?is a potent, selective, slowly reversible and orally bioavailable CXCR2 antagonist that inhibits CXCL8 binding to CXCR2 with pIC50 of 9.1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 53 | In Stock |
|
| 5MG | 69 | In Stock |
|
| 10MG | 113 | In Stock |
|
| 25MG | 215 | In Stock |
|
| 50MG | 332 | In Stock |
|
| 100MG | 494 | In Stock |
|
| 500MG | 1071 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAZD 5069
-
NoteResearch use only, not for human use.
-
Brief DescriptionAZD 5069 (AZD5069)?is a potent, selective, slowly reversible and orally bioavailable CXCR2 antagonist that inhibits CXCL8 binding to CXCR2 with pIC50 of 9.1.
-
DescriptionAZD 5069 (AZD5069)?is a potent, selective, slowly reversible and orally bioavailable CXCR2 antagonist that inhibits CXCL8 binding to CXCR2 with pIC50 of 9.1; weakly inhibits CXCL8 binding to CXCR1 with pIC50<7, and no affinity for CCR2 and CCR5; inhibits neutrophil chemotaxis with pA2 of 9.6, and adhesion molecule expression of 6.9, in response to CXCL1; demonstrates potential activity in acute LPS-induced lung inflammation models.Pancreatic Cancer Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsAZD5069 | AZD-5069
-
PathwayGPCR/G Protein
-
TargetChemokine Receptor
-
RecptorChemokine Receptor
-
Research AreaCancer
-
IndicationPancreatic Cancer
Chemical Information
-
CAS Number878385-84-3
-
Formula Weight476.51
-
Molecular FormulaC18H22F2N4O5S2
-
Purity>98% (HPLC)
-
SolubilityDMSO : 90 mg/mL 188.87 mM
-
SMILESO=S(N1CCC1)(NC2=NC(SCC3=CC=CC(F)=C3F)=NC(O[C@H](C)[C@@H](O)CO)=C2)=O
-
Chemical NameN-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Nicholls DJ, et al. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
2. Jurcevic S, et al. Br J Clin Pharmacol. 2015 Dec;80(6):1324-36.
3. Kirsten AM, et al. Pulm Pharmacol Ther. 2015 Apr;31:36-41.
4. Walters I, et la. Bioorg Med Chem Lett. 2008 Jan 15;18(2):798-803.
molnova catalog
related products
-
VUF11207 fumarate (b...
A potent CXCR7 (ACKR3) agonist with EC50 of 1.6 nM; inducse recruitment of β-arrestin2 and subsequent internalization of CXCR7 in cells.
-
E 6130
A potent, selective, orally available CX3C chemokine receptor 1 (CX3CR1) modulator that inhibits the fractalkine-induced chemotaxis of human peripheral blood NK cells with IC50 of 4.9 nM.
-
IT1t dihydrochloride
A highly potent, selective, orally bioavailable CXCR4 inhibitor with binding IC50 of 8 nM for hCXCR4, IC50 of 1.1 nM in Ca2+-mobilization assays.
